Dr. Nico Lambri, Managing Director“Our extensive experience in clinical assay development and validation, together with our in-house expertise in molecular pathology, immunology, metabolism, and biology, gives us a competitive edge in the market,” says Dr. Nico Lambri, Managing Director, PeploBio.
Having this dynamic lineup of capabilities at its heart enables PeploBio to deliver a streamlined diagnostic service, a comprehensive suite of biomarker testing platforms, and high-quality data to its clientele that encompasses various biopharmaceutical companies. The company’s unique biomarker testing platforms typically combine biomarkers from various disease areas, making them as comprehensive as possible to support precision medicine. PeploBio can also offer testing solutions using different platforms, including PCR, sequencing, serology and flow cytometry. All of this empowers clients to examine medical conditions from different viewpoints to gain the best data possible for pushing the boundaries of their respective fields.
“At PeploBio, we always strive to develop strong relationships with our clients by providing them with the ideal way to succeed,” states Lambri.
Needless to say, all of PeploBio’s solutions are in-tune with its unique customer-centric business model. The company’s Microbiome Wellness Panels for gut microbiome testing are novel qPCR multiplex assays designed to target a wide range of microbes correlated with certain disease areas. With this targeted approach, these testing panels can easily monitor microbe levels and concentration in patients suffering from mental health issues, type-2 diabetes, and lack of immunity. Based on these insights, the company can offer consultation and probiotic advice to help repopulate healthy microbes and reduce unhealthy populations. Similarly, PeploBio delivers all-encompassing, cost-effective sexual health diagnostic assays that leverage molecular and serological techniques.
With its unrivaled service capabilities and attention to detail, PeploBio has gleaned a broad clientele—lab reagents and testing device manufacturers—supporting them with assay development and validation. In many instances, the company has helped them receive CE-IVD marking or get on the CDTA list, which are approved markets regulated within the healthcare industry. PeploBio has also collaborated with numerous biopharmaceutical companies, working with scientists who are developing new tests in the clinical world. One such prestigious project was its collaboration with a client, supporting their study in circulating tumor cells, which aimed to enable the early detection of solid tumors.
Our extensive experience in clinical assay development and validation, together with our in-house expertise in molecular pathology, immunology, metabolism, and biology, gives us a competitive edge in the market
PeploBio’s contribution in combating the spread of COVID-19 was also worth mentioning, given its agility in developing advanced test kits and performing over 10,000 tests per day. To do this, the company had invested on platform development and talent acquisition, while also focusing on logistics, to ensure the seamless movement of testing kits to and from testing centers. PeploBio also went the extra mile and deployed a robust data management system to streamline the operations.
With keen attention on innovation, PeploBio is unlocking the vast opportunities of lateral flow device testing—the technology used in COVID-19 test kits—and applying it in various other infectious diseases areas. The company has developed testing assays to monitor Vitamin D and cholesterol in patients in an efficient and affordable fashion, and quickly access results. Clients can also get confirmation reports, explaining the results and suggesting further actions, when necessary. The company offers customer support and access to healthcare professionals for customers.
In essence, PeploBio is building a world of difference in the biotechnology research space with a service portfolio supported by the extensive experience and expertise of its team of industry experts.
PeploBio and IncellDX Partner to Launch the First Long COVID Test in the UK and EU
Thursday, April 18, 2024
GUILDFORD - PeploBio and IncellDX are launching the first laboratory developed test in the UK and EU to help diagnose Long COVID, providing doctors with accurate insights into personalised treatment approaches using the incellKINE Long Hauler Index technology.
Long COVID affects more than 65 million worldwide. The typical symptoms of Long COVID, ranging from fatigue, brain fog, shortness of breath, insomnia, to a spectrum of cardiovascular issues, are not exclusive to any single condition. This technological breakthrough aims to provide physicians with a definitive tool to differentiate Long COVID from other diseases sharing similar symptoms such as Lyme and ME-CFS.
"Our collaboration with PeploBio marks a pivotal moment in the battle against Long COVID. The incellKINE Long Hauler Index technology enables us to identify a distinctive immunologic profile unique to Long COVID patients, providing a crucial first step for personalised treatment strategies," said Bruce Patterson, M.D., Founder and CEO at IncellDX.
Dr. Nico Lambri, Managing Director at PeploBio said, "Our mission at PeploBio is to drive innovation in diagnostics, and our partnership with IncellDX underscores our commitment to advancing healthcare solutions. The introduction of this test fills a critical gap, empowering healthcare professionals with the tools needed to address the challenges posed by Long COVID."
PeploBio and IncellDX Partner to Launch the First Long COVID Test in the UK and EU
Monday, April 22, 2024
GUILDFORD - PeploBio and IncellDX are launching the first laboratory developed test in the UK and EU to help diagnose Long COVID, providing doctors with accurate insights into personalised treatment approaches using the incellKINE Long Hauler Index technology.
Long COVID affects more than 65 million worldwide. The typical symptoms of Long COVID, ranging from fatigue, brain fog, shortness of breath, insomnia, to a spectrum of cardiovascular issues, are not exclusive to any single condition. This technological breakthrough aims to provide physicians with a definitive tool to differentiate Long COVID from other diseases sharing similar symptoms such as Lyme and ME-CFS.
"Our collaboration with PeploBio marks a pivotal moment in the battle against Long COVID. The incellKINE Long Hauler Index technology enables us to identify a distinctive immunologic profile unique to Long COVID patients, providing a crucial first step for personalised treatment strategies," said Bruce Patterson, M.D., Founder and CEO at IncellDX.
Dr. Nico Lambri, Managing Director at PeploBio said, "Our mission at PeploBio is to drive innovation in diagnostics, and our partnership with IncellDX underscores our commitment to advancing healthcare solutions. The introduction of this test fills a critical gap, empowering healthcare professionals with the tools needed to address the challenges posed by Long COVID."
